Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co., Ltd. has entered into an absorption-type company split agreement with Japan Tobacco Inc. to acquire its pharmaceutical business. This strategic move, effective December 25, 2025, aims to enhance Shionogi’s market position by integrating Japan Tobacco’s pharmaceutical operations, potentially impacting stakeholders by expanding Shionogi’s product offerings and market reach.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2900.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, known for developing and marketing pharmaceutical products. The company focuses on creating innovative treatments and solutions in the healthcare industry.
Average Trading Volume: 2,243,111
Technical Sentiment Signal: Buy
Current Market Cap: Yen2345.3B
See more data about 4507 stock on TipRanks’ Stock Analysis page.